Jackson Lab Acquires NY Stem Cell Foundation

The Jackson Laboratory has completed its acquisition of the New York Stem Cell Foundation, designed to create “one of the most powerful nonprofit engines for biomedical discovery.”

The acquisition combines Jackson Lab’s expertise in genetics and mouse models with NYSCF’s advanced stem cell and automation technologies, according to an Oct. 20 announcement. 

“Bringing JAX and NYSCF together marks a turning point for biomedical research,” said Jackson president and CEO Lon Cardon.

“The future isn’t about choosing one model over another, it’s about integrating them.

“By bringing together mouse, cell and AI models, we will increase success and reduce the costs of life-changing research not only at JAX and NYSCF, but across the scientific community.”

Research Platforms

The acquisition fosters the development of more advanced, predictive research platforms to help scientists uncover disease mechanisms earlier and target therapies for Alzheimer’s, cancer, diabetes, Parkinson’s, and other diseases.

“From the beginning, NYSCF has been driven by the urgency to get cures to patients,” said Daniel Paull, who led foundation efforts to combine automation, imaging and AI to uncover hidden disease features.

He now serves as Jackson’s vice president of discovery and platform development.

The integrated JAX–NYSCF organization will continue to operate as a nonprofit.

“Joining with JAX powers that urgency with an even stronger scientific engine,” Paull said.

“Together, we can move discoveries forward earlier and with greater precision, reducing the costly failures that too often derail later-stage clinical trials.” 

The integrated JAX–NYSCF organization will continue to operate as a nonprofit, maintaining NYSCF’s presence in New York and expanding JAX’s international network of research campuses in Maine, Connecticut, California, Florida, and Japan.